IMMUNIC, INC. (IMUX) Form 8-K — Aug 11, 2026
Immunic reported a Q2 2026 net loss of $34.1 million, or $0.80 per share, versus a $26.8 million loss a year earlier, with R&D expense of $25.9 million and G&A of $9.4 million. Cash and equivalents stood at $155.1 million at June 30, 2026 following the February 2026 oversubscribed private placement, which the company says funds operations into late 2027. On governance, the board appointed Elena Ridloff, CFO of Sionna Therapeutics and former CFO of ACADIA Pharmaceuticals, as a Class I director effective August 6, 2026, with an inaugural option grant to purchase 50,740 shares vesting monthly over three years.
Key figures
- Guidance
- Top-line data from twin Phase 3 ENSURE trials in relapsing MS expected by end of 2026; NDA submission planned mid-2027 if positive with potential approval in 2028; Phase 3 progressive MS trial initiation planned later in 2026; cash expected to fund operations into late 2027.
- Total Assets
- 159169000
- Cash Position
- 155100000
- Shares Outstanding
- 13644467
- Cash Runway
- into late 2027
- Cash Dec312025
- 15483000
- Severance Bonus
- 276375
- Ga Expense Q22025
- 5714000
- Ga Expense Q22026
- 9396000
- Rnd Expense Q22025
- 21369000
- Rnd Expense Q22026
- 25931000
- Severance Lump Sum
- 670000
- Healthcare Reimbursement
- up to EUR 1,500 per month for 18 months
- Weighted Avg Shares Q22026
- 42513839
- Legal Fee Reimbursement Cap
- 20000
- Consulting Retainer Monthly
- EUR 15,000 for 12 months
- Director Option Grant Shares
- 50740
- Total Operating Expenses Q22026
- 35327000
Price after filing
Close on the filing date to close N calendar days later (from $14.30). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.